Entzündung und Nephronenverlust

• Antragsteller: Professor Dr. Hans-Joachim Anders
• Fachliche Zuordnung: Nephrologie
• Förderung: Förderung von 2017 bis 2022
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 326693426

• Erstellungsjahr: 2022

Zusammenfassung der Projektergebnisse

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes.Front. Immunol., Sec. Alloimmunity and Transplantation, Vol. 10. 2019, 1223.
  Lei, Y., Devarapu, S.K., Motrapu, M., Cohen, C.D., Lindenmeyer, M.T., Moll, S., Kumar, S.V., Anders, H.J.
  
• Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI. J Am Soc Nephrol. Vol. 30. 2019, Issue 10, pp. 1857-1869.
  Mulay S.R., Honarpisheh M.M., Foresto-Neto O., Shi C., Desai J., Zhao Z.B., Marschner J.A., Popper B., Buhl E.M., Boor P., Linkermann A., Liapis H., Bilyy R., Herrmann M., Romagnani P., Belevich I., Jokitalo E., Becker J.U., Anders H.J.
  
• Crystal Clots as Therapeutic Target in Cholesterol Crystal Embolism. Circulation Research, Vol. 126. 2020, Issue 8: e37-e52.
  Shi C., Kim T., Steiger S., Mulay S.R., Klinkhammer B.M., Bäuerle T., Melica M.E., Romagnani ., Möckel D., Baues M., Mammadova-Bach E., Yang L., Brouns S.L., Heemskerk J.W., Braun A., Lammers T., Boor P., Anders H.J.
  
• Drug testing for residual progression of diabetic kidney disease in mice beyond therapy with metformin, ramipril, and empagliflozin.Journal of the American Society of Nephrology, Vol. 31. 2020, Issue 8, pp. 1729-1745.
  Motrapu M., Swiderska M.K., Mesas I., Marschner J.A., Lei Y., Velenzuela L.M., Fu J., Lee K., Angelotti M.L., Antonelli G., Romagnani P., Anders H.J., Anguiano L.
  
• Lupus nephritis. Nature Reviews Disease Primers, Vol. 6. 2020, Article number 7.
  Anders H.J., Saxena R., Zhao M.H., Parodis I., Salmon J.E., Mohan C.
  
• Only hyperuricemia with crystalluria but not asymptomatic hyperuricemia drives progression of chronic kidney disease. J Am Soc Nephrol. Vol. 31. 2020, Issue 12, pp. 2773-2792 .
  Sellmayr M., Hernandez-Petzsche M.R., Ma Q., Krüger N., Liapis H., Brink A., Lenz B., Angelotti M.L., Gnemmi V., Kuppe C., Kim H., Bindels E.M.J., Taijti F., Saez-Rodriiguez, J., Lech M., Kramann R., Romagnani P., Anders H.J., Steiger S.
  
• Podocytopathies. Nature Reviews Disease Primers Vol. 6. 2020, Issue 1, Article number: 68.
  Kopp J.B., Anders H.J., Susztak K., Podesta M.A., Remuzzi G., Hildebrandt F., Romagnani P.
  
• A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas-lpr mice with proliferative lupus nephritis predicts low effect size. Kidney International, Vol. 99. 2021, Issue 6, pp. 1331-1341.
  Lei Y., Sehnert B., Voll R.E., Jacobs-Cachá C., Soler M.J., Sanchez-Niño M.D., Ortiz A, Bülow R.D., Boor P., Anders H.J.
  
• Acute kidney injury. Nature Reviews Disease Primers, Vol. 7. 2021, Issue 1, Article number: 52.
  Kellum J.A., Romagnani P., Ashuntantang G., Ronco C., Rarbock A., Anders H.J.
  
• Nephron overload as a therapeutic target to maximize kidney lifespan. Nature Reviews Nephrology, Vol. 18. 2022, pp. 171–183.
  Luyckx V.A., Rule A.D., Tuttle K.R., Delanaye P., Liapis H., Gandjour A., Romagnani P., Anders H.J.